|
|
|
|
Novel analytical technologies like Droplet Digital PCR (ddPCR) provide a more rapid and robust approach to nucleic acid quantification for therapeutic development that better aligns with the industry need for better sensitivity, accuracy, and precision. This relatively new form of PCR offers distinct advantages for DNA and RNA quantification.
|
|
|
|
|
Explore two projects that exemplify the scope and diversity of Fujifilm's ongoing research and technical innovations in Kaisei, Japan. The overarching theme across these projects is a focus on improving efficiency and productivity in biopharmaceutical manufacturing while also reducing the cost of goods through process intensification.
|
|
|
|
|
The journey towards preparing a GMP facility for an allogeneic cell therapy product’s commercialization began with the construction of a cell therapy facility. Review the challenges, triumphs, and lessons learned that have shaped an evolution from facility construction to a fully operational, patient-focused CDMO.
|
|
|
|
|
Fujifilm's history as an innovator company provides a unique ability to assist partners as they advance their own CGT programs. Explore insights about the challenges encountered as an innovator working with external organizations and how these experiences have shaped current practices and our vision for the evolving relationship with CDMOs.
|
|
|
|
|
Human-made extracellular vesicles (EVs) show promise as next-gen therapeutics. More easily manufactured and shipped, these are naturally biocompatible and outperform synthetic carriers in safety and stability, delivering therapeutic cargo directly to target cells. However, there remain significant technical hurdles to their wider commercial potential.
|
|
|
|
|
|
|
